What Misvik Biology does

Misvik Biology is a privately held Finnish oncology firm founded in 2014 and headquartered in Turku, Finland. According to its self-description, the company develops a platform for the assessment of solid cancers and offers technology solutions for testing, positioning it within the cancer diagnostics and laboratory services segment of the life-sciences tools market. The stated functional scope spans both an assessment platform (implying analytical or interpretive capability applied to solid-tumor samples) and testing technology solutions (implying wet-lab or assay-based product/service components). The company operates with a very small team (1-10 employees per firmographic data) and has no public disclosures regarding revenue, pricing, customers, or distribution channels.

The business model cannot be characterized with precision from the available source data. There is no disclosed pricing model, no named customer logos, no segment breakdown between enterprise (hospital, pharma) and academic buyers, and no evidence of recurring-revenue mechanics such as subscriptions, licensing, or per-test fees. The company has no disclosed funding rounds, no M&A activity, no partnership announcements, and no regulatory actions on record in the inputs. Its website (misvik.com) returned only a loader/verification page during data collection, so no first-party product documentation, technical architecture, or scientific publication list was extractable. The company appears to operate as a small, privately held specialty diagnostics entity without observable commercial scale signals.

For diligence purposes, the critical evidence gaps are: (i) no management team roster; (ii) no patent, publication, or regulatory filing record; (iii) no customer or revenue data; (iv) no funding history; and (v) no verifiable first-party product detail beyond the one-line self-description. Any investment thesis built on Misvik Biology will need primary-source validation of its scientific platform, commercial pipeline, and revenue base before defensible conclusions can be drawn.

Name

Misvik Biology

Website

https://misvik.com

Company type

Private

Founded year

2014

Headcount range

1–10 employees

Short description

Misvik Biology is a privately held Finnish oncology firm (Turku, founded 2014, 1-10 employees) that develops a platform for assessing solid cancers and offers related testing technology solutions, serving the cancer diagnostics market.

Ownership category

akta.pro rank

Headquarters

HQ city

Turku

HQ country

Finland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Core offering

Misvik Biology is an oncology firm that develops a platform for the assessment of solid cancers and offers technology solutions for testing. The company provides tools and services aimed at evaluating solid tumor characteristics to support cancer research and clinical decision-making.

Differentiator

Problem solved

Functional benefit

Products and services

• Solid Cancer Assessment Platform
• Cancer Testing Technology Solutions

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Personalis: Cancer genomics company offering tumor profiling assays (e.g., NeXT Personal) for solid tumor characterization. Comparable as a technology-platform solid cancer testing company.
• Guardant Health: Specializes in liquid biopsy and genomics for solid tumor profiling, including the Guardant360 CDx test. Comparable as a cancer testing platform with a strong technology focus.
• Tempus Labs: AI-enabled precision medicine company that runs multi-modal testing (DNA, RNA, imaging) on solid tumors to inform treatment decisions. Closely comparable as a technology-driven solid cancer assessment platform.
• Caris Life Sciences: Provides molecular profiling and AI-driven testing for solid tumors via its MI Profile and Caris Assure platforms. Direct competitor in the solid cancer assessment and testing space.
• Champions Oncology: Provides TumorGraft technology and ex vivo testing services for solid tumor drug response assessment. Comparable as a smaller-scale solid cancer testing platform serving pharma R&D.

Regional players

• OncoDNA: Belgium-based company offering comprehensive solid tumor molecular profiling and treatment guidance across European markets. Comparable as a European-region solid cancer assessment and testing platform.
• Fios Genomics: UK-based bioinformatics and analytics services company for life sciences, including oncology biomarker discovery. Comparable as a European-region data and analytics provider for cancer research.

Emerging players

• Notable Labs: Functional precision medicine platform that tests patient tumor samples against drug panels to predict response. Comparable as a smaller cancer assessment platform with a testing focus.
• Certis Oncology Solutions: Functional precision oncology company that tests patient-derived solid tumor models for drug response. Comparable as a smaller emerging player in solid tumor functional assessment.

Broad incumbents

• Foundation Medicine: A leading molecular profiling company for solid tumors, now part of Roche. Comparable as a comprehensive solid cancer assessment platform serving oncologists and pharma, though at significantly larger scale.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/MisvikB

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Misvik Biology